|
An open-label, randomized cross-over bioavailability and extension study of oral paclitaxel and HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours. |
| |
Christopher G. C. A. Jackson |
Research Funding - Athenex |
Patents, Royalties, Other Intellectual Property - Athenex |
Travel, Accommodations, Expenses - Athenex |
| |
|
Travel, Accommodations, Expenses - Roche |
| |
Katherine Francis Bayston |
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Travel, Accommodations, Expenses - MSD; Roche |
| |
|
|
|
Stock and Other Ownership Interests - Zentech (I) |
Research Funding - Zentech (Inst) |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Athenex; Merck |
| |
|
|
|
Stock and Other Ownership Interests - Athenex |
Travel, Accommodations, Expenses - Athenex |
| |
|
|
|
Stock and Other Ownership Interests - Lilly; Merck |
Travel, Accommodations, Expenses - Kinex |
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
|
|
Stock and Other Ownership Interests - Kinex |
Research Funding - Kinex (Inst) |
Patents, Royalties, Other Intellectual Property - Kinex |